Developing the first drug to treat the symptoms of Lewy body dementia and Parkinson’s disease
Submitting InstitutionNewcastle University
Unit of AssessmentPsychology, Psychiatry and Neuroscience
Summary Impact TypeHealth
Research Subject Area(s)
Medical and Health Sciences: Clinical Sciences, Neurosciences, Public Health and Health Services
Summary of the impact
Dementia is one of the greatest problems facing society today, both in financial terms and in terms
of the quality of life of patients and caregivers. Newcastle research identified that cholinesterase
inhibitors (CHEIs), originally licenced for use in Alzheimer's disease, would be of greater benefit in
two other types of dementia; Lewy body dementia and Parkinson's disease. CHEIs are now
recommended in national and international guidelines as a treatment for the cognitive and
psychiatric symptoms associated with both of these conditions, which previously had no effective
treatment. CHEIs are also licenced worldwide for use in Parkinson's dementia, and are used off-
licence across the world as a first-line treatment for dementia with Lewy bodies.
Key Newcastle researchers
- Professor Ian McKeith, Professor of Old Age Psychiatry (1994-2010, Strategic Research
- Professor Elaine Perry, Honorary Professor (1991-2009), Strategic Research Advisor
(2009-2011, Emeritus Professor 2012-date)
- Professor Robert Perry, Clinical Reader/Consultant (1980-1999), Clinical
Professor/Consultant (1999-2009), Emeritus Professor (2009-date).
Newcastle research into cholinesterase inhibitors
Cholinesterase inhibitors reduce the breakdown of the neurotransmitter acetylcholine, maintaining
levels in the brain and therefore preserving communication between brain cells. CHEIs were first
developed as a treatment for the symptoms of Alzheimer's disease (AD), including memory loss
and anxiety, and were found to significantly improve cognition and activities of daily living (as
measured using scales such as the Alzheimer's Disease Assessment Scale — Cognitive subscale).
In the early 1990s, Newcastle researchers identified that there was a greater deficiency of
acetylcholine in post-mortem human brain tissue of patients with dementia with Lewy bodies (DLB)
than in those with AD (R1). The Newcastle group therefore suggested that CHEIs might be
especially effective in DLB. Prior to this, no effective treatments were available, since antipsychotic
drugs (also known as neuroleptics) can cause severe, even fatal, adverse reactions in these
patients (Rolinski et al. 2012 Cochrane review PMID: 22419314). The development of diagnostic
criteria for DLB allowed the first therapeutic trials to be carried out, which led to the introduction of
diagnostic criteria for DLB in 1996 (R2).
Following early feasibility studies in Newcastle (R3), McKeith led the first multi-centre trial, which
demonstrated that CHEIs were indeed effective in DLB (R4). The results of this study showed that
patients given the CHEI rivastigmine exhibited significantly fewer psychotic symptoms such as
delusion and hallucination, and were significantly faster and better scoring at computerised
cognitive tests than the placebo group. Following these results, CHEI treatment for DLB was taken
up in clinical practice (see Section 4).
This work paved the way for similar treatment to be applied in Parkinson's disease dementia
(PDD). The results of a preliminary trial by the same group of Newcastle investigators (R5) showed
that patients given rivastigmine showed significant improvement over baseline scores in terms of
hallucinations, sleep disturbance and cognitive scores, and that caregiver distress was also
significantly reduced. A parallel study of the CHEI donepezil, in both DLB and PDD patients,
confirmed these effects, and gave the first indication of clinical efficacy and acceptable side effects
in these two populations (R6). Based upon this evidence and using the methodology of the earlier
Newcastle DLB study, the effects of rivastigmine in PDD were confirmed by a large multi-centre,
placebo-controlled, randomised controlled trial (Emre et al. 2004, DOI: 10.1056/NEJMoa041470),
which led to the licensing of CHEIs in PDD.
References to the research
(Scopus citation data as at 31.7.13, Newcastle researchers in
R1. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A,
Griffiths M, McKeith IG and Perry RH (1994) Neocortical cholinergic activities differentiate
Lewy body dementia from classical Alzheimer's disease. NeuroReport 5, 747-749. DOI;
10.1097/00001756-199403000-00002. Cited by 187.
R2. McKeith, IG, Galasko, D, Kosaka, K, Perry, EK, Dickson, DW, Hansen, LA, Salmon, DP,
Lowe, J, Mirra, SS, Byrne, EJ, Lennox, G, Quinn, NP, Edwardson, JA, Ince, PG, Bergeron,
C, Burns, A, Miller, BL, Lovestone, S, Collerton, D, Jansen, ENH, Ballard, C, De Vos, RAI,
Wilcock, GK, Jellinger, KA and Perry, RH. (1996). Consensus guidelines for the clinical and
pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB
international workshop. Neurology 47 (5): 1113-1124 DOI: 10.1212/WNL.47.5.1113. 2549
R3. McKeith, IG; Grace, JB; Walker, Z; Byrne, EJ; Wilkinson, D; Stevens, T and Perry, EK.
(2000) Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from
an open trial. International Journal of Geriatric Psychiatry. 15: 5, 387-392. DOI:
10.1002/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9. 115 citations.
R4. McKeith IG, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R
and Spiegel R (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised,
double-blind, placebo-controlled international study. Lancet 356, 2031-2036. DOI:
10.1016/S0140-6736(00)03399-7. 719 citations.
R5. Reading PJ, Luce AK and McKeith IG (2001). Rivastigmine in the treatment of parkinsonian
psychosis and cognitive impairment: Preliminary findings from an open trial. Movement
Disorders 16(6), 1171-1174. DOI: 10.1002/mds.1204. 180 citations.
R6. Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson
J, Sanders J and McKeith IG (2005). A comparison of the efficacy of donepezil in
Parkinson's disease with Dementia and Dementia with Lewy bodies. International Journal of
Geriatric Psychiatry 20 (10): 938-944. DOI: 10.1002/gps.1381. 57 citations.
Relevant funding awards
1994-1995 Mental Health Foundation North East £1,000. Which patients with Lewy body dementia
are at risk of severe side effects from major tranquilisers.
1998-2001 Novartis Pharmaceuticals £239,972. Prospective, multicentre, randomised double blind
placebo-controlled exploratory study to evaluate the safety tolerability.
1999-2004 Medical Research Council (MRC) £1,130,524. Dementia with Lewy bodies: Diagnosis
2001-2002 Pfizer Limited £50,000. A pilot study into the effects of donepezil on cognitive
impairment and neuropsychiatric features in patients with dementia with Lewy bodies and
2005-2009 MRC £955,675.00 BH041206 - Support for Newcastle Brain Tissue Bank.
Details of the impact
The challenge of dementia
Dementia is one of the largest issues facing society today, with 35.6 million people affected
worldwide — a prevalence of nearly 5% in those aged over 65. The 2009 World Alzheimer's report
(EV a) estimates that dementia has an annual global cost of $315 billion, and contributes nearly
1% of all Disability Adjusted Life Years (DALYs). However, since dementia is largely a disease of
older people, in the over 60s it accounts for 4.1% of DALYs and 11.3% of Years Lived with
The most common type of dementia after Alzheimer's disease is dementia with Lewy bodies (DLB)
which, together with the related disorder Parkinson's disease dementia (PDD), comprise 15-20%
of all dementias in older people (EV b, c, d). DLB and PDD are characterised by persistent and
disabling psychiatric symptoms, which cannot be managed using standard anti-psychotic
(neuroleptic) treatments because of increased morbidity specific to DLB, such as deterioration of
cognition and increased parkinsonism. European guidelines from 2012 state: "[patients with DLB]
show a propensity to have exaggerated adverse reactions to neuroleptic drugs, with a significantly
increased morbidity and mortality." (EV e). This specific sensitivity was originally recognised by
Newcastle researchers (McKeith et al. 1992 BMJ, PMID: 1356550).
The impact of Newcastle research on guidelines
Newcastle work found that CHEIs significantly reduce psychiatric symptoms and improve
cognition, without substantial risk of side effects. As a consequence, CHEIs are now widely
recommended for use in both DLB and PDD. This is the first time treatment has been available to
manage the symptoms of these conditions. NICE clinical guideline 42, updated in March 2011, (EV
f, p 36) recommends that people with DLB should be offered a CHEI under certain conditions:
"People with DLB who have non-cognitive symptoms causing significant distress to the individual,
or leading to behaviour that challenges, should be offered an acetylcholinesterase inhibitor." The
guidelines include R4 as the only trial to compare the CHEI rivastigime to placebo in DLB.
These guidelines also report that "Overall, the results of the economic analysis indicate that
acetylcholinesterase inhibitors are likely to be a cost-effective treatment option for people with DLB
experiencing non-cognitive symptoms" (EV f, pg 257), drawing on R4 as the sole source of
The 2011 Consensus statement from the British Association of Psychopharmacology (EV b) gives
a category A (strongest) recommendation of the use of CHEIs in both DLB and PDD: "There is
type I evidence [strongest] to support treatment with cholinesterase inhibitors in ... both dementia
with Lewy bodies and Parkinson's disease dementia and that both cognitive and neuropsychiatric
symptoms improve" (pg. 1004). Within these guidelines, R4 forms part of the evidence that
"[randomised controlled trials] of cholinesterase inhibitors have demonstrated benefit in cognitive
and non-cognitive symptoms in DLB and PDD" (pg. 1003). These guidelines also state that CHEIs
improve patient quality of life, for example alleviating symptoms such as hallucinations, apathy,
anxiety and sleep disorders (pg. 1003).
Recent guidelines from the European Federation of Neurological Societies (2012, EV e) also
recognise the benefit of CHEIs in DLB patients, stating that "patients with DLB respond to
cholinesterase inhibitors with improvement in cognitive and psychiatric symptoms" (pg. 1176). In
terms of patient quality of life, these guidelines state that "Cholinesterase inhibitors... also may
decrease or prevent psychotic symptoms, particularly hallucinations... and DLB" (pg. 1177). These
guidelines draw on the 2012 Cochrane review by Rolinski et al., in which the only paper to support
use of CHEIs in DLB is R4.
The impact of Newcastle research on drug prescribing in clinical practice
Newcastle work has revolutionised the drug management of patients with DLB and PDD, allowing
the disabling symptoms to be managed for the first time. Using the results and methodology of
Newcastle research into CHEI use in DLB, a later study (Emre et al.) showed that rivastigmine was
effective in PDD. This provided evidence for the Medicines and Healthcare products Regulatory
Agency (MHRA) granting the first UK licence to use CHEIs in PDD in November 2009 (licence
number PL 10622/0450, EV g). Since then, six further licences have been granted to companies
worldwide, including the US and UK (EV g). Trials to support similar licensing for DLB remain
ongoing, although practice guidelines (EV b, e, f) support the widespread off-licence use of CHEIs
The Professor of Biological Psychiatry at the University of Southampton (EV h), states: "As a
university researcher in dementia I can state that cholinesterase inhibitors ... are widely prescribed
across the UK and the world for the condition of dementia with Lewy bodies... The evidence
produced by Prof McKeith was sufficient for the prescribing of these drugs to gain a drug licence
and was sufficiently compelling for inclusion in the 2011 British Association of
Psychopharmacology treatment guidelines... It is common practice [to prescribe] these drugs
which have resulted in much patient benefit for both the patient's cognition and other associated
The National Clinical Director for Dementia, NHS England (EV i), has stated: "The recognition of
Lewy bodies as a cause of dementia and its unique clinical characteristics have been made
possible by the work and descriptions of the Newcastle group ... the basic science and cutting
edge translational research which highlighted the benefits of the cholinesterase drugs ... has had a
significant influence on clinical practice."
Newcastle work showed that CHEIs were effective in patients with DLB and PDD, whose
symptoms could not be managed using existing drugs. This allowed an extension of the use of
CHEIs, demonstrated by their recommendation in national and European guidelines, and MHRA
licensing since 2009. CHEIs are now widely used to treat the disabling symptoms of DLB and
PDD, improving patient quality of life.
Sources to corroborate the impact
EV a. The 2009 World Alzheimer's report:
EV b. O'Brien, J and Burns, A. (2011) Clinical practice with anti-dementia drugs: a revised
(second) consensus statement from the British Association for Psychopharmacology.
Journal of Psychopharmacology. 25(8) 997-1019.
EV c. Rahkonen et al. (2003). Dementia with Lewy bodies according to the consensus criteria in
a general population aged 75 years or older. Journal of Neurology, Neurosurgery and
EV d. The Alzheimer's Society factsheet: rarer causes of dementia
EV e. Sorbi, S., et al. (2012). EFNS-ENS Guidelines on the diagnosis and management of
disorders associated with dementia. European Journal of Neurology. 19: 1159-1179.
EV f. NICE Clinical Guideline 42, updated March 2011:
EV g. Licence numbers PL 35574/0018, PL 00037/0654-7, PL 35533/0014, PL 17277/0060-63
(also PL 17277/0120-0127), PL 24668/0117-20 and PL 18157/0240. Full information can
be found by entering the licence numbers at www.mhra.gov.uk .
EV h. The Professor of Biological Psychiatry at the University of Southampton. Contact details
available on request.
EV i. The Consultant Old Age Psychiatrist, Manchester Mental Health and Social Care Trust,
also the National Clinical Director for Dementia, NHS England. Contact details available on